Posted On: 01/02/2015 11:54:53 AM
Post# of 30066
a little more clarity please...anyone.
the latest PR regarding Jan14th conference highlighting Lympro data. a poster pointed out "highly significant" vs previous "weak data". It appears shareholders are anticipating new and better results; however, I recall 80% accuracy with a strong "p" value. Q: Are these the same known data sets or are they mulitvariate and fully optimized vs stage independent? It is not clear if this is the expected "shot heard round the world" creating significant pps upward movement or more intrinsic value building. According to recent posts shareholders might be receiving more of the same. Any thoughts?
Mosserman
the latest PR regarding Jan14th conference highlighting Lympro data. a poster pointed out "highly significant" vs previous "weak data". It appears shareholders are anticipating new and better results; however, I recall 80% accuracy with a strong "p" value. Q: Are these the same known data sets or are they mulitvariate and fully optimized vs stage independent? It is not clear if this is the expected "shot heard round the world" creating significant pps upward movement or more intrinsic value building. According to recent posts shareholders might be receiving more of the same. Any thoughts?
Mosserman
(0)
(0)
